Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: flickerful who wrote (387)	1/3/1998 10:12:00 PM
From: 5,17,37,5,101,...	Read Replies (1) \| Respond to of 756

This excerpt is taken from the Financial Times, 1/3/98. Simply imagine Ivax in addition to Pfizer for reasons previously posted. ft.com then go to search under "glaxo" "Most importantly, the pressure to develop more products at greater speed will put renewed pressure on drug companies to consolidate. The possibility of two large companies, say Glaxo and Pfizer, getting together to corner more than their fair share of new product leads is not inconceivable - and the repercussions would reverberate through their peer group. On top of that, the industry is coming up to a new wave of patent expiries, which will leave some groups looking vulnerable. In 1995, the top 28 drug companies had 6 per cent of their pharmaceuticals sales coming off patent in the following three years. In 2000, it will be more than 20 per cent. Good volume growth and high share prices have allowed managements to ignore the urge to merge over the past two years. But consolidation is coming back on to the agenda." Jackson